Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination

Publication Type:

Journal Article

Source:

Vaccine, Volume 29, Number 5, pp. 1045-1052 (2011)

ISBN:

0264-410X

DOI Name (links to online publication)

10.1016/j.vaccine.2010.11.061

Keywords:

skin; intradermal vaccination; liposomes; tlr ligands; lipid vesicle size; synthetic lipopeptides; dendritic cells; influenza vaccine; delivery systems; in-vivo; adjuvants; DNA; induction; immunization

Abstract:

Enhanced immunogenicity of subunit antigens can be achieved by antigen encapsulation in liposomes and the addition of immune potentiators. In this study we co-encapsulated ovalbumin (OVA) and a Toll-like receptor (TLR) ligand (PAM(3)CSK(4) (PAM) or CpG) in cationic liposomes and investigated the effect of the formulations on dendritic cell (DC) maturation in vitro and on the immune response in mice after intradermal immunisation. Co-encapsulation of PAM did not affect the OVA content of the liposomes, but co-encapsulation of CpG led to a decrease in OVA content by 25%. After liposomal encapsulation, both ligands retained the ability to activate TLR-transfected HEK cells, though PAM only induced activation at elevated concentrations. DC maturation induced by liposome-based adjuvant formulations was superior compared to the free adjuvants. Encapsulation of PAM and CpG in liposomes did not influence the total IgG titres compared to the antigen/adjuvant solution, but OVA/CpG liposomes shifted the IgG1/IgG2a balance more to the direction of IgG2a compared to non-encapsulated CpG. Moreover, only this formulation resulted in IFN-gamma production by restimulated splenocytes from immunised mice. These data show that co-encapsulation of antigen and immune potentiator in cationic liposomes, can affect the type of immune response generated after intradermal immunisation. (C) 2010 Elsevier Ltd. All rights reserved.

19/04/2011